The Role of Gut Microbiota in Hypertension
| Status: | Recruiting |
|---|---|
| Conditions: | High Blood Pressure (Hypertension) |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - 80 |
| Updated: | 2/17/2019 |
| Start Date: | July 2014 |
| End Date: | December 2019 |
| Contact: | Eileen M Handberg, PhD |
| Email: | handbem@ufl.edu |
| Phone: | 352-273-8944 |
Hypertension is the single most prevalent risk factor for heart diseases, heart failure,
kidney failure and stroke. About 1 in 3 adults in the United States have hypertension.
Approximately 28-30% of hypertensive patients suffer from resistant hypertension (RH).
Inflammation has been implicated in the pathogenesis of the hypertension. Additional data
suggests the involvement of gut microbiota in host normal cardiovascular functions and
pathophysiology. Accumulating evidence demonstrates that antibiotic treatment benefits
patients with acute coronary syndromes and reduces the incidence of ischemic cardiovascular
events. Even though these studies did not address effects of antibiotic treatment on the gut
microbiota, it is possible that gut microbiota could affect neurologic inflammation. Finally,
intestinal microbiota has recently been proposed to modulate blood pressure (BP) through
production of short-chain fatty acids. In order to investigate this, the investigators
hypothesize that gut microbiota is involved in the neuroinflammation-mediated initiation and
establishment of RH, and targeting gut microbiota by minocycline would produce beneficial
outcomes in RH.
kidney failure and stroke. About 1 in 3 adults in the United States have hypertension.
Approximately 28-30% of hypertensive patients suffer from resistant hypertension (RH).
Inflammation has been implicated in the pathogenesis of the hypertension. Additional data
suggests the involvement of gut microbiota in host normal cardiovascular functions and
pathophysiology. Accumulating evidence demonstrates that antibiotic treatment benefits
patients with acute coronary syndromes and reduces the incidence of ischemic cardiovascular
events. Even though these studies did not address effects of antibiotic treatment on the gut
microbiota, it is possible that gut microbiota could affect neurologic inflammation. Finally,
intestinal microbiota has recently been proposed to modulate blood pressure (BP) through
production of short-chain fatty acids. In order to investigate this, the investigators
hypothesize that gut microbiota is involved in the neuroinflammation-mediated initiation and
establishment of RH, and targeting gut microbiota by minocycline would produce beneficial
outcomes in RH.
This is a prospective cohort design. This study will enroll 388 subjects: 81 patients without
HTN as a reference group, 81 patients with controlled HTN, 55 patients with uncontrolled HTN,
55 with remodeled RH, and 81 patients with RH to characterize gut microbiota composition.
Subjects will provide stool samples for analysis. Subjects will also provide a blood sample
for inflammatory marker and stem cell analysis.
HTN as a reference group, 81 patients with controlled HTN, 55 patients with uncontrolled HTN,
55 with remodeled RH, and 81 patients with RH to characterize gut microbiota composition.
Subjects will provide stool samples for analysis. Subjects will also provide a blood sample
for inflammatory marker and stem cell analysis.
Inclusion Criteria:
- age >18 and <80
- is competent and willing to provide consent
Inclusion criteria for each subject group:
- Control subjects will have a systolic BP <140mmHg with no cardiovascular disease
- Patients with controlled hypertension
- Patients with uncontrolled hypertension
- Resistant hypertension subjects will have systolic blood pressure (BP) ≥140 mmHg
despite ≥3 anti-hypertensive medications of different classes one of which should be a
diuretic
- Patients who are no longer RH subjects and have normal blood pressure
- Subjects participating in NCT 02133872 will be eligible to participate
Exclusion Criteria:
- currently pregnant or have been pregnant in the last 6 months;
- antibiotic treatment within 2 months of study enrollment;
- currently taking a medication (e.g., antibiotic, anti-inflammatory agents,
glucocorticoids or other immune modulating medications);
- unwilling to discontinue vitamin or supplements, including probiotics, potentially
affecting gut microbiota (vitamins/supplements and medications that possibly affect
the gut microbiota should be discontinued for at least 2wks prior to stool
collection);
- history of intestinal surgery, inflammatory bowel disease, celiac disease, lactose
intolerance, chronic pancreatitis or other malabsorption disorder.
We found this trial at
1
site
Gainesville, Florida 32610
Principal Investigator: Carl J Pepine, MD
Phone: 352-273-8944
Click here to add this to my saved trials
